熱門資訊> 正文
自行车治疗报告第一季度业绩
2025-05-01 22:14
- Bicycle Therapeutics press release (NASDAQ:BCYC): Q1 GAAP EPS of -$0.88
- Revenue of $10M (-48.8% Y/Y).
- Cash and cash equivalents were $793.0 million as of March 31, 2025, compared to $879.5 million as of December 31, 2024.
More on Bicycle Therapeutics
- Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted
- Bicycle Therapeutics: Trading At Cash, Underwhelming But Not Unsalvageable Data
- Seeking Alpha’s Quant Rating on Bicycle Therapeutics
- Historical earnings data for Bicycle Therapeutics
- Financial information for Bicycle Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
